Hirotsugu Kenmotsu

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.4K citations

Oncology, Adjuvant Chemotherapy, Pathology +6

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer

Hirotsugu Kenmotsu, Tateaki Naito, Madoka Kimura et al. · Journal of Thoracic Oncology · 2011 · 226 citations · Full text

Inflammatory Lung Disease, Advanced Lung Disease, Lung Inflammation +9

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

Tateaki Naito, Fumihiro Tanaka, Akira Ono et al. · Journal of Thoracic Oncology · 2012 · 185 citations · Full text

Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer

Madoka Kimura, Tateaki Naito, Hirotsugu Kenmotsu et al. · Supportive Care in Cancer · 2014 · 177 citations

Prognostic Impact, Cancer Cachexia, Medicine +9

Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System

Masahito Hosokawa, Hirotsugu Kenmotsu, Yasuhiro Koh et al. · PLoS ONE · 2013 · 175 citations · Full text